By Bill Berkrot New YORK (Reuters) - Investment banker turned biotech chief executive, Robert Bradway, staked a claim as a savvy dealmaker with Amgen Inc's successful acquisition of Onyx Pharmaceuticals Inc for more than $10 billion. In doing so, he managed to avoid falling into traps that an inexperienced CEO might make with the stakes so high, while potentially quieting some criticism over the choice of a former banker to lead the world's largest biotechnology company. ...
via Health News Headlines - Yahoo! News http://news.yahoo.com/bradways-patient-dealmaking-brings-onyx-amgen-231332395.html
via Health News Headlines - Yahoo! News http://news.yahoo.com/bradways-patient-dealmaking-brings-onyx-amgen-231332395.html
No comments:
Post a Comment